Published in Parkinsonism Relat Disord on August 01, 2004
Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev (2009) 2.86
Viral parkinsonism. Biochim Biophys Acta (2008) 1.57
Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev (2008) 1.52
Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. J Neurosci (2010) 1.01
Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug Alcohol Depend (2014) 0.90
Methamphetamine abuse, HIV infection, and neurotoxicity. Int J Physiol Pathophysiol Pharmacol (2009) 0.87
Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention - A Comparison with Parkinson's Disease. Neuropsychol Rev (2015) 0.78
Hemichorea-hemiballismus as an initial manifestation in a Moroccan patient with acquired immunodeficiency syndrome and toxoplasma infection: a case report and review of the literature. Pan Afr Med J (2011) 0.78
Tic Disorder: An Unusual Presentation of Neurotoxoplasmosis in a Patient with AIDS. Case Rep Neurol (2010) 0.75
Movement disorders of probable infectious origin. Ann Indian Acad Neurol (2014) 0.75
HIV, visceral leishmaniasis and Parkinsonism combined with diabetes mellitus and hyperuricaemia: A case report. Cases J (2008) 0.75
Selective vulnerability of striatal D2 versus D1 dopamine receptor-expressing medium spiny neurons in HIV-1 Tat transgenic male mice. J Neurosci (2017) 0.75
Opsoclonus-myoclonus-ataxia syndrome and HIV seroconversion. J Neurol (2009) 0.75
Reversible progressive supranuclear palsy-like phenotype as an initial manifestation of HIV infection. Neurol Sci (2011) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol (2004) 6.14
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol (2004) 5.18
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One (2008) 3.85
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord (2006) 3.13
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
"Psychogenic movement disorders": they are what they are. Mov Disord (2014) 2.56
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol (2008) 2.27
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med (2009) 2.04
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98
Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet (2002) 1.98
Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol (2003) 1.91
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Dose-effect relationships between manganese exposure and neurological, neuropsychological and pulmonary function in confined space bridge welders. Occup Environ Med (2006) 1.81
Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis (2007) 1.79
JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol (2005) 1.79
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol (2011) 1.73
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA (2004) 1.71
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol (2008) 1.60
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol (2004) 1.55
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med (2003) 1.52
Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr (2011) 1.52
Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol (2008) 1.47
Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr (2012) 1.44
Parkinsonism due to manganism in a welder: neurological and neuropsychological sequelae. Neurotoxicology (2006) 1.42
The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol (2007) 1.42
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol (2004) 1.38
The pathogenesis of cell death in Parkinson's disease. Neurology (2006) 1.38
Sequelae of fume exposure in confined space welding: a neurological and neuropsychological case series. Neurotoxicology (2006) 1.36
Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci (2002) 1.35
Urinary NGAL marks cystic disease in HIV-associated nephropathy. J Am Soc Nephrol (2009) 1.34
The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int (2008) 1.33
Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy. Am J Pathol (2004) 1.28
Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil (2002) 1.27
A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One (2012) 1.27
The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One (2012) 1.27
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol (2005) 1.27
Long-term monitoring of gait in Parkinson's disease. Gait Posture (2006) 1.25
JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol (2011) 1.25
Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress. J Biol Chem (2004) 1.24
Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem (2002) 1.22
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol (2002) 1.22
Cocaine hijacks σ1 receptor to initiate induction of activated leukocyte cell adhesion molecule: implication for increased monocyte adhesion and migration in the CNS. J Neurosci (2011) 1.21
Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr (2013) 1.21
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis (2008) 1.18
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord (2007) 1.17
Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr (2011) 1.16
Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol (2003) 1.15
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport (2002) 1.15
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology (2013) 1.14
Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. PLoS Pathog (2011) 1.14
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett (2002) 1.11
Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy. J Neurovirol (2013) 1.10
Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis (2013) 1.10
Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol (2003) 1.10
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS (2012) 1.09
Segmentation of Brain Immunohistochemistry Images Using Clustering of Linear Centroids and Regional Shapes. J Imaging Sci Technol (2008) 1.09
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol (2008) 1.08
Overexpression of torsinA in PC12 cells protects against toxicity. J Neurochem (2004) 1.08
Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol (2008) 1.08
Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging (2005) 1.08
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology (2008) 1.07
Lifetime suicidal ideation and attempt are common among HIV+ individuals. J Affect Disord (2011) 1.06
Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study. J Neurosurg (2004) 1.05
HIV-1-infected and/or immune-activated macrophages regulate astrocyte CXCL8 production through IL-1beta and TNF-alpha: involvement of mitogen-activated protein kinases and protein kinase R. J Neuroimmunol (2008) 1.04
Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction. Am J Respir Cell Mol Biol (2010) 1.02
Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol (2003) 1.01
Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis. PLoS One (2013) 0.99
p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem (2006) 0.99
Brain inflammation is a common feature of HIV-infected patients without HIV encephalitis or productive brain infection. Curr HIV Res (2014) 0.98
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother (2010) 0.98
Mechanisms of HIV-tat-induced phosphorylation of N-methyl-D-aspartate receptor subunit 2A in human primary neurons: implications for neuroAIDS pathogenesis. Am J Pathol (2010) 0.98
Differential effects of HIV infected macrophages on dorsal root ganglia neurons and axons. Exp Neurol (2007) 0.97
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J (2003) 0.97
Substance abuse increases the risk of neuropathy in an HIV-infected cohort. Muscle Nerve (2012) 0.96
The roles of ethnicity and antiretrovirals in HIV-associated polyneuropathy: a pilot study. J Acquir Immune Defic Syndr (2009) 0.95
Treatment of levodopa-induced motor complications. Mov Disord (2008) 0.95
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr (2012) 0.95
Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem (2008) 0.95